Elimelech Nesher

Dr. Elimelech Nesher

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ASAlfiya Safina
Alfiya Safina
PCPeter Cheney
Peter Cheney
MPMahadeb Pal
Mahadeb Pal
LBLeonid Brodsky
Leonid Brodsky
AIAlexander Ivanov
Alexander Ivanov
Katerina GurovaKaterina Gurova
Katerina Gurova
Transitions of B-DNA to alternative DNA structures (ADS) can be triggered by negative torsional strain, which occurs during replication and transcription, and may lead to genomic instability. However, how ADS are recognized in cells is unclear. We found that the binding of candidate anticancer drug, curaxin, to cellular DNA results in uncoiling of nucleosomal DNA, accumulation of negative supercoiling and conversion of multiple regions of genomic DNA into left-handed Z-form. Histone chaperone FACT binds rapidly to the same regions via the SSRP1 subunit in curaxin-treated cells. In vitro binding of purified SSRP1 or its isolated CID domain to a methylated DNA fragment containing alternating purine/pyrimidines, which is prone to Z-DNA transition, is much stronger than to other types of DNA. We propose that FACT can recognize and bind Z-DNA or DNA in transition from a B to Z form. Binding of FACT to these genomic regions triggers a p53 response. Furthermore, FACT has been shown to bind to other types of ADS through a different structural domain, which also leads to p53 activation. Thus, we propose that FACT acts as a sensor of ADS formation in cells. Recognition of ADS by FACT followed by a p53 response may explain the role of FACT in DNA damage prevention.

26 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAnatoly Kreinin
Anatoly Kreinin
SLSerah Lisson
Serah Lisson
ENElimelech Nesher
Elimelech Nesher
JSJenny Schneider
Jenny Schneider
JBJosef Bergman
Josef Bergman
APAlbert Pinhasov
Albert Pinhasov
Though the role of brain derived neurotrophic factor (BDNF) as a marker for major depressive disorder (MDD) and antidepressant efficacy has been widely studied, the role of BDNF in distinct groups of patients remains unclear. We evaluated the diagnostic value of BDNF as a marker of disease severity measured by HAM-D scores and antidepressants efficacy among MDD patients. Fifty-one patients who met DSM-IV criteria for MDD and were prescribed antidepressants and 38 controls participated in this study. BDNF in serum was measured at baseline, 1st, 2nd and 8th treatment weeks. Depression severity was evaluated using the Hamilton Rating Scale for Depression (HAM-D). BDNF polymorphism rs6265 (val66met) was genotyped. We found a positive correlation between blood BDNF levels and severity of depression only among untreated women with severe MDD (HAM-D>24). Serum BDNF levels were lower in untreated MDD patients compared to control group. Antidepressants increased serum BDNF levels and reduced between-group differences after two weeks of treatment. No correlations were observed between BDNF polymorphism, depression severity, duration of illness, age and BDNF serum levels. Further supporting the role of BDNF in the pathology and treatment of MDD, we suggest that it should not be used as a universal biomarker for diagnosis of MDD in the general population. However, it has diagnostic value for the assessment of disease progression and treatment efficacy in individual patients.

14 March 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ENElimelech Nesher
Elimelech Nesher
ASAlfiya Safina
Alfiya Safina
IAIeman Aljahdali
Ieman Aljahdali
SPScott Portwood
Scott Portwood
EWEunice S. Wang
Eunice S. Wang
Katerina GurovaKaterina Gurova
Katerina Gurova
Precisely how DNA-targeting chemotherapeutic drugs trigger cancer cell death remains unclear, as it is difficult to separate direct DNA damage from other effects in cells. Recent work on curaxins, a class of small-molecule drugs with broad anticancer activity, shows that they interfere with histone–DNA interactions and destabilize nucleosomes without causing detectable DNA damage. Chromatin damage caused by curaxins is sensed by the histone chaperone FACT, which binds unfolded nucleosomes becoming trapped in chromatin. In this study, we investigated whether classical DNA-targeting chemotherapeutic drugs also similarly disturbed chromatin to cause chromatin trapping of FACT (c-trapping). Drugs that directly bound DNA induced both chromatin damage and c-trapping. However, chromatin damage occurred irrespective of direct DNA damage and was dependent on how a drug bound DNA, specifically, in the way it bound chromatinized DNA in cells. FACT was sensitive to a plethora of nucleosome perturbations induced by DNA-binding small molecules, including displacement of the linker histone, eviction of core histones, and accumulation of negative supercoiling. Strikingly, we found that the cytotoxicity of DNA-binding small molecules correlated with their ability to cause chromatin damage, not DNA damage. Our results suggest implications for the development of chromatin-damaging agents as selective anticancer drugs. Significance: These provocative results suggest that the anticancer efficacy of traditional DNA-targeting chemotherapeutic drugs may be based in large part on chromatin damage rather than direct DNA damage. Cancer Res; 78(6); 1431–43. ©2018 AACR.

1 October 2010 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YFYuval Feder
Yuval Feder
ENElimelech Nesher
Elimelech Nesher
AOAriel Ogran
Ariel Ogran
AKAnatoly Kreinin
Anatoly Kreinin
EMEwa Malatynska
Ewa Malatynska
APAlbert Pinhasov
Albert Pinhasov

1 January 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
ENElimelech Nesher
Elimelech Nesher
MGMoshe Gross
Moshe Gross
SLSerah Lisson
Serah Lisson
TTTatiana Tikhonov
Tatiana Tikhonov
GYGal Yadid
Gal Yadid
APAlbert Pinhasov
Albert Pinhasov

5 February 2018 in eLife
Verified
Journal Article
Open access
KLKaterina Leonova
Katerina Leonova
ASAlfiya Safina
Alfiya Safina
ENElimelech Nesher
Elimelech Nesher
PSPoorva Sandlesh
Poorva Sandlesh
RPRachel Pratt
Rachel Pratt
Katerina GurovaKaterina Gurova
Katerina Gurova
Cellular responses to the loss of genomic stability are well-established, while how mammalian cells respond to chromatin destabilization is largely unknown. We previously found that DNA demethylation on p53-deficient background leads to transcription of repetitive heterochromatin elements, followed by an interferon response, a phenomenon we named TRAIN (Transcription of Repeats Activates INterferon). Here, we report that curaxin, an anticancer small molecule, destabilizing nucleosomes via disruption of histone/DNA interactions, also induces TRAIN. Furthermore, curaxin inhibits oncogene-induced transformation and tumor growth in mice in an interferon-dependent manner, suggesting that anticancer activity of curaxin, previously attributed to p53-activation and NF-kappaB-inhibition, may also involve induction of interferon response to epigenetic derepression of the cellular ‘repeatome’. Moreover, we observed that another type of drugs decondensing chromatin, HDAC inhibitor, also induces TRAIN. Thus, we proposed that TRAIN may be one of the mechanisms ensuring epigenetic integrity of mammalian cells via elimination of cells with desilenced chromatin.